THIS WEBPAGE IS FOR AUSTRALIAN HEALTHCARE PROFESSIONALS ONLY | Order samples | Request rep appointment | Patient resources |
What is UROREC?
|
UROREC (silodosin) is a highly selective α1A receptor blocker indicated for the relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia in adult men alleviating a range of BPH symptoms.1,2 |
Why choose UROREC?
†In vitro data does not necessarily predict human clinical effects
|
Minimal cardiovascular impact2* |
Highest improvement in bladder outlet obstruction among alpha blockers3‡ |
|
Improvement in nocturia4 |
*Minimal effect on supine blood pressure; no effect on ECG intervals or cardiac repolarisation;
orthostatic hypotension similar to placebo (more common in elderly although usually mild and resolves with continued treatment);
can be co-administered with antihypertensives while monitoring for possible adverse reactions.2
‡Based on alpha 1a/alpha 1b affinity ratio; study used indirect comparisons.3
How does UROREC work differently from other alpha blockers? |
||||||||||||||||||||||||||||||||
UROREC has high affinity for the α1A adrenergic receptors in the prostate, the bladder, and the prostatic urethra. By this mechanism, it relaxes the smooth muscle in these organs, easing urinary flow and other symptoms of BPH.2 |
||||||||||||||||||||||||||||||||
|
|
UROREC RPBS information7
silodosin 8 mg capsule, 30 |
silodosin 4 mg‡ capsule, 30 |
|
Item Code |
12077P |
12079R |
General Patient Charge |
$6.60 |
$6.60 |
Max. quantity of packs - 1; max. number of repeats - 5
Authority required – Benign prostatic hyperplasia. Clinical criteria: Patient must have lower urinary tract symptoms.
8 mg starting dose. No dose adjustment required in elderly.2‡
‡4 mg starting dose recommended in patients with moderate renal impairment; please see PI for full information.
The efficacy of UROREC in the relief of LUTS (as measured by IPSS total score) was:
|
CHANGES IN IPSS TOTAL SCORE AT 12 WEEKS (PRIMARY ENDPOINT) |
Figure adapted from Chapple, CR. et al. 20118 The study was not designed to detect a difference in efficacy between UROREC and tamsulosin8 |
|||
Learn more about this study |
PBS Information: This product is not listed on the PBS. For RPBS Information refer to PBS Schedule |
Please review the Full Product Information before prescribing. |
Abbreviations: LUTS = lower urinary tract symptoms; BPH = benign prostatic hyperplasia; RPBS = Repatriation Schedule of Pharmaceutical Benefits; IPSS = International Prostate Symptom Score; vs = versus; ITT = intent-to-treat (all subjects who had a baseline IPSS assessment and at least one valid post baseline IPSS assessment); vs. = versus; PP = per-protocol (all subjects who completed the study without any major protocol violation); NS = non-significant. |
References: 1. Roehrborn CG, et al. Adv Ther (2016) 33: 2110–2121. 2. UROREC Approved Product Information. 3. Fusco F et al. Adv Ther 2017; 24:773–783. 4. Eisenhardt A, et al. World J Urol 2014; 32:1119–1125. 5. Rossi M, et al. Drug Des Devel Ther. 2010; 4: 291–7. 6. Kaplan SA, et al. Alpha-blocker therapy: current update. Rev Urol. 2005; 7(Suppl 8): S34–42. 7. https://www.pbs.gov.au/browse/rpbs [Accessed 3 May 2022]. 8. Chapple CR, et al. Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe. Eur Urol. 2011; 59: 342–52. |
UROREC® is sold by Mayne Pharma International Pty Ltd under license from Recordati Ireland, Ltd., Ringaskiddy, Ireland and Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan. Mayne Pharma International Pty Ltd. ABN 88 007 870 984. 1538 Main North Road, Salisbury South, SA 5106. T: 1300 081 849. URO0091. Date of preparation: May 2022. |